News | May 26, 2025
Kilitch Drugs posts consolidated Q4 FY25 PAT at Rs. 10.21 Cr
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
For the full year FY25, net profit soared 12x to Rs 345 crore
Allopurinol is used to prevent or lower high uric acid levels in the blood
Amlodipine and Atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
Subscribe To Our Newsletter & Stay Updated
